Generative AI will continue to be a driving force in innovation, but its future must be sustainable by design.

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

Isomorphic Labs, a Google-backed AI company, is set to begin human trials for cancer drugs designed by AI, raising both hope ...

QpiAI has an aggressive development roadmap. The company aims to introduce a 64-qubit quantum machine (codenamed "Kaveri") by late 2026 or early 2027, with client access proposed shortly thereafter.

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

In this episode presented by IQVIA, BioSpace's head of insights Lori Ellis discusses the evolving role of local qualified ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

Drug discovery has long been criticized for its slow, costly, and failure-prone nature. Traditional approaches, particularly ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...